Navigation Links
PDL BioPharma Announces First Quarter 2009 Financial Results
Date:5/7/2009

- Revenues From Continuing Operations Increase 25 Percent to $62.6 Million -

- Conference Call Today at 4:30 p.m. Eastern Time -

INCLINE VILLAGE, Nev., May 7 /PRNewswire-FirstCall/ -- PDL BioPharma, Inc. (PDL) (Nasdaq: PDLI) today reported financial results for the first quarter ended March 31, 2009.

Total revenues from continuing operations for the first quarter of 2009 were $62.6 million, a 25 percent increase from $50.2 million for the same period in 2008. The increase was primarily due to increases in royalty revenues driven by higher product sales of Avastin(R), Herceptin(R) and Lucentis(R), which are marketed by Genentech, Inc., a subsidiary of F. Hoffman-La Roche Ltd., and sales of Tysabri(R), which is marketed by Elan Corporation, Plc. Royalty revenues are based on fourth quarter product sales by PDL's licensees and include those for Synagis(R), which is marketed by MedImmune, Inc.

"We were pleased to begin fulfilling the goal of income distribution to stockholders by paying our first post-spin-off dividend in April, a result of the revenues and profits PDL is generating from royalties on a diversified portfolio of successful products," said John McLaughlin, president and chief executive officer of PDL BioPharma. "Our new and focused strategy seeks to optimize our assets to benefit stockholders without the diversion, expense, and considerable risk of research and development."

Total general and administrative expenses from continuing operations in the first quarter of 2009 were $4.7 million compared with $12.7 million in the first quarter of 2008. The decrease was primarily driven by the Company's reduced cost structure. Significant expense items for the first quarter of 2009 included $1.6 million in legal fees for patent prosecution, patent defense and corporate complia
'/>"/>

SOURCE PDL BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sinobiopharma Secures Rights to Seven Key Patents
2. China Biologic Products Receives $5.3 Million Order from Largest Biopharmaceutical Distributor in India
3. Sinobiopharma Reports a 141% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
4. Sinobiopharma Reports a 41% Increase in Revenues From Unaudited Financial Results for the 9 Month Period Ended February 28, 2009
5. Helix BioPharma to Present at the BioFinance 2009 Conference
6. Keryx Biopharmaceuticals, Inc. Announces Michael P. Tarnok as Interim Chairman and Chief Executive Officer
7. 2009 Prix Galien USA Now Accepting Nominations for Top Prize in Biopharmaceutical Research and Development
8. Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research
9. Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry
10. XTL Biopharmaceuticals Ltd. Receives Notification of Delisting Determination by NASDAQ Listing Qualifications Panel
11. Sinobiopharma, Inc. Appoints New Director of Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/5/2015)... ... August 05, 2015 , ... FluidX’s ... from legacy tubes, with 2D barcode labels on the lid, to modern sample ... 2D barcodes in 1 second, using FluidX’s IntelliCode software, which deals easily with ...
(Date:8/5/2015)... ... August 05, 2015 , ... MTI-GlobalStem, ... the launch of an updated corporate identity, including new company name, logo and ... in 2009. The company moved into a new, joint facility in 2014 to ...
(Date:8/4/2015)... Blythewood, South Carolina (PRWEB) , ... August 05, ... ... the first edition of the “Product Handbook – the complete product line.” ... steam system components. , “This new product handbook consolidates our complete standard product ...
(Date:8/4/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), a ... for the quarter ending June 30, 2015. Highlights included: ... 2015 , The final cost of the Sarnia ... million above the high end of the estimate communicated ... 10%) , The company announced commercial collaborations in ...
Breaking Biology Technology:RURO Announces FreezerPro® 7 Integration with Top-down 2D barcode scanners by FluidX 2MTI-GlobalStem Announces Updated Company Identity and Website 2MTI-GlobalStem Announces Updated Company Identity and Website 3Spirax Sarco releases Product Handbook 2BioAmber Reports Second Quarter 2015 Financial Results 2BioAmber Reports Second Quarter 2015 Financial Results 3BioAmber Reports Second Quarter 2015 Financial Results 4BioAmber Reports Second Quarter 2015 Financial Results 5BioAmber Reports Second Quarter 2015 Financial Results 6BioAmber Reports Second Quarter 2015 Financial Results 7BioAmber Reports Second Quarter 2015 Financial Results 8BioAmber Reports Second Quarter 2015 Financial Results 9BioAmber Reports Second Quarter 2015 Financial Results 10BioAmber Reports Second Quarter 2015 Financial Results 11BioAmber Reports Second Quarter 2015 Financial Results 12
... a biotechnology company developing novel regenerative therapies to ... $3.4 million Series A investment led by North ... JumpStart Inc., Fletcher Spaght Investments, Glengary LLC, Ohio ... Gen Ltd. and a significant number of individuals. ...
... A novel microscopy method at the Department of ... the reactions that limit widespread deployment of fuel cell ... electrochemical strain microscopy that enables them to examine the ... which may reveal ways to redesign or cut the ...
... 15, 2011 A new post-hoc sub-analysis of an ... – those identified as the "core clinical cohort" population ... aspirin) was associated with a 26 percent relative risk ... myocardial infarction or stroke, compared to treatment with clopidogrel ...
Cached Biology Technology:SironRX Therapeutics Raises $3.4 Million Series A 2ORNL microscopy generates new view of fuel cells 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 2Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 3Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 4Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 5Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 6Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 7Effient® (Prasugrel) Showed Significant 26 Percent Reduction in Cardiovascular Events Over Clopidogrel in New Core Clinical Cohort Population Sub-Analysis of the TRITON-TIMI 38 Pivotal Study 8
(Date:8/4/2015)... , Aug. 04, 2015 ... ) has announced the addition of the ... Software, and Service), Sub-Segment (Computer Forensics, Network ... Tool Types, Service, Vertical and Region - ... their offering. By Component (Hardware, ...
(Date:8/4/2015)...  AMRI (NASDAQ: AMRI ) today reported financial and operating ... Highlights: , Second quarter contract revenue of $ ... , Adjusted contract margins of 26 % ... $0.05 decrease in EPS from royalties in the current quarter ... "We are very pleased to present another strong financial quarter, ...
(Date:8/3/2015)... SAN JOSE, Calif. , Aug. 3, 2015 /PRNewswire/ ... developer of human interface solutions, today announced that members ... investment community at the Pacific Crest Global Technology Leadership ... Mountain Time. The conference will be held at the ... The presentation may include forward-looking information. ...
Breaking Biology News(10 mins):Digital Forensics Market - The Market Represents a Compound Annual Growth Rate (CAGR) of 11.3% From 2015 to 2020 2AMRI Announces Second Quarter 2015 Results 2AMRI Announces Second Quarter 2015 Results 3AMRI Announces Second Quarter 2015 Results 4AMRI Announces Second Quarter 2015 Results 5AMRI Announces Second Quarter 2015 Results 6AMRI Announces Second Quarter 2015 Results 7AMRI Announces Second Quarter 2015 Results 8AMRI Announces Second Quarter 2015 Results 9AMRI Announces Second Quarter 2015 Results 10AMRI Announces Second Quarter 2015 Results 11AMRI Announces Second Quarter 2015 Results 12AMRI Announces Second Quarter 2015 Results 13AMRI Announces Second Quarter 2015 Results 14AMRI Announces Second Quarter 2015 Results 15AMRI Announces Second Quarter 2015 Results 16AMRI Announces Second Quarter 2015 Results 17AMRI Announces Second Quarter 2015 Results 18AMRI Announces Second Quarter 2015 Results 19AMRI Announces Second Quarter 2015 Results 20AMRI Announces Second Quarter 2015 Results 21AMRI Announces Second Quarter 2015 Results 22AMRI Announces Second Quarter 2015 Results 23AMRI Announces Second Quarter 2015 Results 24
... Cambridge and Boston, MA. Wed. July 4, 2012 One ... after treatment. In the case of many forms of cancer, ... eradicate cancer cells in the lab, but often produce only ... in the field of cancer research has been and remains: ...
... new type of scholarly articles, which are rapidly gaining ... publications that describe data sets and provide an opportunity ... citation and re-use of the published data. Data Papers ... among the international organization Global Biodiversity Information Facilities ...
... coast of North America is reaching the level of the ... by a researcher at the University of British Columbia. ... Bulletin , examined stomach contents of beached northern fulmars on ... Washington and Oregon, U.S.A. "Like the canary in the ...
Cached Biology News:Tumor microenvironment helps skin cancer cells resist drug treatment 2Tumor microenvironment helps skin cancer cells resist drug treatment 3Tumor microenvironment helps skin cancer cells resist drug treatment 4A new type of data papers designed to publish online interactive keys identifying biodiversity 2Seabirds study shows plastic pollution reaching surprising levels off coast of Pacific Northwest 2
Mouse polyclonal antibody to BTG2 - BTG family, member 2...
...
... DNA quantitation kit is used to quantitate double-stranded ... of RNA or protein. With this kit, DNA ... be detected with a VersaFluor or other fluorometer. ... 10 ng per ml to 5 micrograms per ...
... colony stimulating factors for assays of mouse ... and fetal liver. Suitable for the ... CFU-GEMM when added to methylcellulose at a ... erythropoietin. Will also support growth of ...
Biology Products: